Literature DB >> 17239289

Non-rash skin toxicities associated with novel targeted therapies.

Mario E Lacouture1, Scott A Boerner, Patricia M Lorusso.   

Abstract

Many novel targeted agents have emerged against a variety of malignancies. Although papulopustular rash is the most commonly observed side effect associated with many of these agents, several non-rash skin toxicities have been identified that frequently result in the delay or discontinuation of anticancer therapy. These toxicities include skin hyperpigmentation, xerosis, pruritus, hair growth and color abnormalities, periungual and nail alterations, and hand-foot skin reaction. It is important to recognize these toxicities, so that they can be diagnosed early and treatment or dose modification can be initiated, if necessary. This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17239289     DOI: 10.3816/clc.2006.s.012

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  6 in total

1.  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Authors:  Yevgeniy Balagula; Katherine Barth Huston; Klaus J Busam; Mario E Lacouture; Paul B Chapman; Patricia L Myskowski
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

Review 2.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

3.  Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.

Authors:  Joshua M Donaldson; Csaba Kari; Ruben C Fragoso; Ulrich Rodeck; John C Williams
Journal:  Cancer Biol Ther       Date:  2009-11-07       Impact factor: 4.742

Review 4.  The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Authors:  Alyssa Fischer; Shenhong Wu; Alan L Ho; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2013-01-24       Impact factor: 3.850

Review 5.  Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.

Authors:  Beth Eaby-Sandy; Carolyn Grande; Pamela Hallquist Viale
Journal:  J Adv Pract Oncol       Date:  2012-05

Review 6.  The eyelash follicle features and anomalies: A review.

Authors:  Sarah Aumond; Etty Bitton
Journal:  J Optom       Date:  2018-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.